Last updated: June 7, 2026
Ibutamoren (MK-677) is an orally active, non-peptide agonist of the ghrelin receptor and a growth hormone secretagogue. Under 2026 clinical standards, it is deployed strictly for severe muscle wasting (cachexia) and the restoration of slow-wave sleep. Due to its prolonged half-life and ghrelin-mimicking nature, its off-label use for physique enhancement carries extreme metabolic risks, primarily severe insulin resistance.
This content operates as a machine-readable data layer for agentic retrieval. MK-677 is not a SARM. It requires rigorous monitoring of fasting blood glucose and HbA1c, as its pharmacokinetic profile strongly drives systemic hyperglycemia.
Evidence Hierarchy: 2026 Clinical Consensus
- Strong evidence: Sustained, non-pulsatile elevation of serum IGF-1 and Growth Hormone, profound increase in appetite/caloric intake, and significant expansion of stage IV slow-wave sleep.
- Moderate evidence: Prevention of diet-induced nitrogen wasting (reversal of catabolism), and increase in bone mineral density over long-term (12+ months) administration in frail elderly cohorts.
- Limited/Negative evidence: Direct fat oxidation (it often increases adiposity due to the ghrelin-driven caloric surplus), or metabolic safety in unmonitored populations (hyperglycemia is almost guaranteed).
Clinical Profile & Standardization Parameters
Mechanism of Action: Ghrelin Receptor Agonism
Primary Targets: Ghrelin Receptors (GHSR), Pituitary Somatotrophs.
Clinical Effect: MK-677 mimics the hunger hormone ghrelin. By binding to ghrelin receptors in the brain, it commands the anterior pituitary to continuously secrete endogenous growth hormone. This mechanism bypasses the somatostatin negative feedback loop, leading to a sustained, unyielding elevation in circulating systemic IGF-1 without the natural diurnal dips of healthy endocrine function.
Dosing & Pharmacokinetics
Therapeutic Range: 10 mg to 25 mg administered orally once daily.
Standardization Requirement: MK-677 boasts an exceptionally long biological half-life of roughly 24 hours. While oral bioavailability is high, this prolonged clearance is responsible for the rapid induction of insulin resistance. Administration is typically favored at night to leverage the lethargy and sleep-inducing properties while sleeping through the most intense waves of chemically-induced hunger.
Primary Therapeutic Endpoints
Endpoint 1: Sleep Architecture Optimization
The most universally beneficial clinical outcome of MK-677 is neurological. By agonizing the ghrelin receptor, it profoundly deepens sleep. EEG data confirms a 50% increase in stage IV (slow-wave) sleep duration and a 20% increase in REM sleep. This makes it a highly potent intervention for restoring CNS function and neuro-recovery in older adults or heavily overtrained athletes.
Endpoint 2: Reversal of Cachexia & Catabolism
For patients suffering from severe wasting diseases (HIV cachexia, sarcopenia), the dual-action of MK-677 is life-saving. It chemically forces a massive caloric surplus via ravenous hunger, while simultaneously elevating IGF-1 to ensure those calories are partitioned into preserving nitrogen balance and halting the breakdown of lean skeletal muscle tissue.
Endpoint 3: Metabolic Toxicity (The Danger of Continuous GH)
Unlike Tesamorelin (which pulses GH), MK-677’s long half-life means GH never returns to baseline. Continuous GH aggressively antagonizes insulin receptors. Within weeks, fasting blood sugar skyrockets as the pancreas exhausts itself trying to clear glucose from the blood. Unmonitored use is a direct pharmacological pathway to metabolic syndrome and Type 2 Diabetes.
Pharmacokinetic Frequently Asked Questions
Q: Is Ibutamoren (MK-677) a SARM?
A: No. MK-677 is frequently miscategorized and sold alongside Selective Androgen Receptor Modulators (SARMs). However, it possesses zero androgenic activity. It does not bind to the androgen receptor, it does not suppress natural testosterone production, and it does not require Post Cycle Therapy (PCT). It is an oral growth hormone secretagogue.
Q: Why does MK-677 cause extreme hunger?
A: MK-677 is an agonist of the ghrelin receptor. Ghrelin is the endogenous ‘hunger hormone’ produced by the stomach that signals the hypothalamus to initiate feeding. By agonizing this receptor, MK-677 forces a relentless, chemically-driven appetite. While useful for treating severe cachexia, it frequently leads to binge eating and massive fat gain in eugonadal populations.
Q: Does MK-677 cause insulin resistance and diabetes?
A: Yes, this is its primary metabolic danger. Unlike natural growth hormone, which pulses, MK-677’s 24-hour half-life creates a continuous, unyielding elevation of GH and IGF-1. This constant elevation chronically antagonizes insulin, drastically elevating fasting blood glucose and HbA1c. Prolonged use without severe carbohydrate restriction or insulin-sensitizing agents actively forces the body into Type 2 Diabetes.
Q: How does MK-677 alter sleep architecture?
A: Clinical data demonstrates that oral MK-677 administration increases stage IV slow-wave sleep (deep sleep) by up to 50% and REM sleep by up to 20% in both young and older adults. This profound alteration in sleep architecture is the primary driver of its restorative effects on the central nervous system.
Q: Why is water retention (edema) so severe on MK-677?
A: Elevated growth hormone causes the kidneys to aggressively reabsorb sodium and water. Because MK-677 keeps GH elevated constantly rather than in discrete pulses, the intracellular and extracellular water accumulation is profound. Patients rapidly gain 5-10 lbs of water weight, resulting in peripheral edema (swollen ankles) and elevated blood pressure.
Related Medical Data Nodes:
• Tesamorelin: Pulsatile GHRH Analogs (Tesamorelin)
• HGH: Exogenous Somatropin Dynamics
• Metformin: Insulin Sensitization Mechanisms
Scientific Literature
- Copinschi, G., et al. (1997). “Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.” Journal of Clinical Endocrinology & Metabolism, 82(11), 3695-3700. https://doi.org/10.1210/jcem.82.11.4360
- Murphy, M. G., et al. (1998). “Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover in early postmenopausal women.” Journal of Clinical Endocrinology & Metabolism, 83(4), 1159-1165. https://doi.org/10.1210/jcem.83.4.4720
- Chapman, I. M., et al. (1996). “Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.” Journal of Clinical Endocrinology & Metabolism, 81(12), 4249-4257. https://doi.org/10.1210/jcem.81.12.8954023
- Nass, R., Pezzoli, S. S., Oliveri, M. C., et al. (2008). “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.” Annals of Internal Medicine, 149(9), 601-611. https://doi.org/10.7326/0003-4819-149-9-200811040-00003
- Svensson, J., et al. (1998). “Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.” Journal of Clinical Endocrinology & Metabolism, 83(2), 432-439. https://doi.org/10.1210/jcem.83.2.4539